{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:16:46Z","timestamp":1783613806454,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01172-5","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:47:12Z","timestamp":1783608432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-1948","authenticated-orcid":false,"given":"Sean A.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Pickersgill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-1551","authenticated-orcid":false,"given":"Juan C.","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deaglan J.","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2381-6910","authenticated-orcid":false,"given":"Himanshu","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-4852","authenticated-orcid":false,"given":"James","family":"Janopaul-Naylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Lacuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim A.","family":"Touijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Fainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6791-9324","authenticated-orcid":false,"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behfar","family":"Ehdaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Dallos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"1172_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore, N. D. et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 27, 192\u2013201 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1172_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41585-018-0017-x","volume":"15","author":"G Pignot","year":"2018","unstructured":"Pignot, G. et al. Systemic treatments for high-risk localized prostate cancer. Nat. Rev. Urol. 15, 498\u2013510 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"1172_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer, E. M. et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 21, 1067\u20131096 (2023).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1172_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","volume":"167","author":"GW Hull","year":"2002","unstructured":"Hull, G. W. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167, 528\u2013534 (2002).","journal-title":"J. Urol."},{"key":"1172_CR5","doi-asserted-by":"publisher","first-page":"e2332900","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario, U. G. et al. Biochemical recurrence and risk of mortality following radiotherapy or radical. JAMA Netw. Open 6, e2332900 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1172_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl, K. A., Han, M., Ramos, C. G., Antenor, J. A. & Catalona, W. J. Cancer progression and survival rates following anatomical radical retropubic. J. Urol. 172, 910\u2013914 (2004).","journal-title":"J. Urol."},{"key":"1172_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","volume":"28","author":"M Han","year":"2001","unstructured":"Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. & Walsh, P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28, 555\u2013565 (2001).","journal-title":"Urol. Clin. North Am."},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.euros.2023.08.001","volume":"55","author":"HY Hougen","year":"2023","unstructured":"Hougen, H. Y. et al. Clinical and genomic factors associated with greater tumor mutational burden in prostate cancer. Eur. Urol. Open Sci. 55, 45\u201349 (2023).","journal-title":"Eur. Urol. Open Sci."},{"key":"1172_CR9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","volume":"24","author":"J Stultz","year":"2021","unstructured":"Stultz, J. & Fong, L. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 24, 697\u2013717 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1172_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06110-6","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis. 14, 587 (2023).","journal-title":"Cell Death Dis."},{"key":"1172_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","volume":"36","author":"L Brea","year":"2025","unstructured":"Brea, L. & Yu, J. Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer. Trends Endocrinol. Metab. 36, 855\u2013866 (2025).","journal-title":"Trends Endocrinol. Metab."},{"key":"1172_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1001\/jamaoncol.2023.6817","volume":"10","author":"PD Zang","year":"2024","unstructured":"Zang, P. D. et al. Tumor mutational burden in metastatic castration-resistant prostate cancer and response to checkpoint inhibition. JAMA Oncol. 10, 531\u2013532 (2024).","journal-title":"JAMA Oncol."},{"key":"1172_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700\u2013712 (2014).","journal-title":"Lancet Oncol."},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1158\/1078-0432.CCR-20-1981","volume":"27","author":"DP Petrylak","year":"2021","unstructured":"Petrylak, D. P. et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin. Cancer Res. 27, 3360\u20133369 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471\u2013478 (2019).","journal-title":"JAMA Oncol."},{"key":"1172_CR16","doi-asserted-by":"publisher","first-page":"e0301943","DOI":"10.1371\/journal.pone.0301943","volume":"19","author":"A Anton","year":"2024","unstructured":"Anton, A. et al. An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape. PLoS ONE 19, e0301943 (2024).","journal-title":"PLoS ONE"},{"key":"1172_CR17","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","volume":"41","author":"JE Hawley","year":"2023","unstructured":"Hawley, J. E. et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell 41, 1972\u20131988.e5 (2023).","journal-title":"Cancer Cell"},{"key":"1172_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02973-1","volume":"11","author":"X Long","year":"2020","unstructured":"Long, X. et al. Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration. Cell Death Dis. 11, 779 (2020).","journal-title":"Cell Death Dis."},{"key":"1172_CR19","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-24-0060","volume":"30","author":"MC Dallos","year":"2024","unstructured":"Dallos, M. C. et al. Androgen deprivation therapy drives a distinct immune phenotype in localized. Clin. Cancer Res. 30, 5218\u20135230 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR20","doi-asserted-by":"publisher","first-page":"859785","DOI":"10.3389\/fimmu.2022.859785","volume":"13","author":"A Mulvey","year":"2022","unstructured":"Mulvey, A., Muggeo-Bertin, E., Berthold, D. R. & Herrera, F. G. Overcoming immune resistance with radiation therapy in prostate cancer. Front. Immunol. 13, 859785 (2022).","journal-title":"Front. Immunol."},{"key":"1172_CR21","doi-asserted-by":"publisher","first-page":"688489","DOI":"10.3389\/fonc.2021.688489","volume":"11","author":"C Mao","year":"2021","unstructured":"Mao, C., Ding, Y. & Xu, N. A double-edged sword role of cytokines in prostate cancer immunotherapy. Front. Oncol. 11, 688489 (2021).","journal-title":"Front. Oncol."},{"key":"1172_CR22","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","volume":"26","author":"AZ Obradovic","year":"2020","unstructured":"Obradovic, A. Z. et al. T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin. Cancer Res. 26, 3182\u20133192 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR23","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1158\/1078-0432.CCR-19-3642","volume":"26","author":"WX Hong","year":"2020","unstructured":"Hong, W. X. et al. Intratumoral immunotherapy for early-stage solid tumors. Clin. Cancer Res. 26, 3091\u20133099 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR24","doi-asserted-by":"publisher","first-page":"e1468956","DOI":"10.1080\/2162402X.2018.1468956","volume":"7","author":"DL Bajor","year":"2018","unstructured":"Bajor, D. L. et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology 7, e1468956 (2018).","journal-title":"Oncoimmunology"},{"key":"1172_CR25","doi-asserted-by":"publisher","first-page":"1\u201313","DOI":"10.1097\/CAD.0b013e32835a5ca3","volume":"24","author":"JC Poust","year":"2013","unstructured":"Poust, J. C., Woolery, J. E. & Green, M. R. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs 24, 1\u201313 (2013).","journal-title":"Anticancer Drugs"},{"key":"1172_CR26","doi-asserted-by":"publisher","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","volume":"28","author":"A Marabelle","year":"2017","unstructured":"Marabelle, A., Tselikas, L., de Baere, T. & Houot, R. Intratumoral immunotherapy: using the tumor as the remedy. Ann. Oncol. 28, xii33\u2013xii43 (2017).","journal-title":"Ann. Oncol."},{"key":"1172_CR27","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","volume":"43","author":"JC Osorio","year":"2025","unstructured":"Osorio, J. C. et al. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell 43, 1902\u20131916.e9 (2025).","journal-title":"Cancer Cell"},{"key":"1172_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411\u2013422 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1172_CR29","doi-asserted-by":"publisher","first-page":"e192589","DOI":"10.1001\/jamanetworkopen.2019.2589","volume":"2","author":"MEV Caram","year":"2019","unstructured":"Caram, M. E. V., Ross, R., Lin, P. & Mukherjee, B. Factors associated with use of sipuleucel-T to treat patients with advanced prostate cancer. JAMA Netw. Open 2, e192589 (2019).","journal-title":"JAMA Netw. Open"},{"key":"1172_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt, D. E. et al. Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology. J. Natl Compr. Cancer Netw. 23, 469\u2013493 (2025).","journal-title":"J. Natl Compr. Cancer Netw."},{"key":"1172_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.18.02031","volume":"37","author":"JL Gulley","year":"2019","unstructured":"Gulley, J. L. et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 1051\u20131061 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR32","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1517\/13543780903530678","volume":"19","author":"ES Antonarakis","year":"2010","unstructured":"Antonarakis, E. S. & Carducci, M. A. Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects. Expert Opin. Invest. Drugs 19, 311\u2013314 (2010).","journal-title":"Expert Opin. Invest. Drugs"},{"key":"1172_CR33","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamaoncol.2021.7298","volume":"8","author":"NJ Vogelzang","year":"2022","unstructured":"Vogelzang, N. J. et al. Efficacy and safety of autologous dendritic cell-based immunotherapy, docetaxel, and prednisone vs placebo in patients with metastatic castration-resistant prostate cancer: the VIABLE phase 3 randomized clinical trial. JAMA Oncol. 8, 546\u2013552 (2022).","journal-title":"JAMA Oncol."},{"key":"1172_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","volume":"35","author":"TM Beer","year":"2017","unstructured":"Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40\u201347 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.eururo.2020.07.032","volume":"78","author":"K Fizazi","year":"2020","unstructured":"Fizazi, K. et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur. Urol. 78, 822\u2013830 (2020).","journal-title":"Eur. Urol."},{"key":"1172_CR36","doi-asserted-by":"publisher","first-page":"e2341165","DOI":"10.1001\/jamanetworkopen.2023.41165","volume":"6","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9, T. et al. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw. Open 6, e2341165 (2023).","journal-title":"JAMA Netw. Open"},{"key":"1172_CR37","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance, W. et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J. Urol. 209, 1082\u20131090 (2023).","journal-title":"J. Urol."},{"key":"1172_CR38","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753\u20133758 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz, L. H. et al. RECIST 1.1 \u2014 update and clarification: from the RECIST committee. Eur. J. Cancer 62, 132\u2013137 (2016).","journal-title":"Eur. J. Cancer"},{"key":"1172_CR40","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","volume":"30","author":"AT Lenis","year":"2024","unstructured":"Lenis, A. T. et al. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clin. Cancer Res. 30, 3894\u20133903 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR41","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s43018-024-00894-y","volume":"6","author":"A Marabelle","year":"2025","unstructured":"Marabelle, A. et al. Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial. Nat. Cancer 6, 253\u2013258 (2025).","journal-title":"Nat. Cancer"},{"key":"1172_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat. Med. 28, 144\u2013153 (2022).","journal-title":"Nat. Med."},{"key":"1172_CR43","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO-24-01283","volume":"43","author":"DP Petrylak","year":"2025","unstructured":"Petrylak, D. P. et al. Pembrolizumab plus docetaxel versus docetaxel for previously treated metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-921 trial. J. Clin. Oncol. 43, 1638\u20131649 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR44","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.annonc.2025.05.007","volume":"36","author":"JN Graff","year":"2025","unstructured":"Graff, J. N. et al. Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann. Oncol. 36, 976\u2013987 (2025).","journal-title":"Ann. Oncol."},{"key":"1172_CR45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","volume":"26","author":"N Agarwal","year":"2025","unstructured":"Agarwal, N. et al. Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. Lancet Oncol. 26, 860\u2013876 (2025).","journal-title":"Lancet Oncol."},{"key":"1172_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017).","journal-title":"Genome Med."},{"key":"1172_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"1172_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","volume":"15","author":"LN Chesner","year":"2025","unstructured":"Chesner, L. N. et al. Androgen receptor inhibition increases MHC class I expression and improves immune response in prostate cancer. Cancer Discov. 15, 481\u2013494 (2025).","journal-title":"Cancer Discov."},{"key":"1172_CR49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/(SICI)1097-0045(19971201)33:4<233::AID-PROS2>3.0.CO;2-I","volume":"33","author":"NH Bander","year":"1997","unstructured":"Bander, N. H. et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-\u03b1 and -\u03b3. Prostate 33, 233\u2013239 (1997).","journal-title":"Prostate"},{"key":"1172_CR50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","volume":"7","author":"CG Drake","year":"2005","unstructured":"Drake, C. G. et al. Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen. Cancer Cell 7, 239\u2013249 (2005).","journal-title":"Cancer Cell"},{"key":"1172_CR51","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T","volume":"70","author":"SJ Hall","year":"1997","unstructured":"Hall, S. J., Mutchnik, S. E., Chen, S. H., Woo, S. L. & Thompson, T. C. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir. Int. J. Cancer 70, 183\u2013187 (1997).","journal-title":"Int. J. Cancer"},{"key":"1172_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.cgt.7700004","volume":"6","author":"SJ Hall","year":"1999","unstructured":"Hall, S. J. et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 6, 54\u201363 (1999).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eururo.2005.02.013","volume":"48","author":"RR van der Linden","year":"2005","unstructured":"van der Linden, R. R. et al. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. Eur. Urol. 48, 153\u2013161 (2005).","journal-title":"Eur. Urol."},{"key":"1172_CR54","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969\u2013974 (1998).","journal-title":"JAMA"},{"key":"1172_CR55","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/cgt.2013.56","volume":"20","author":"A Rojas-Mart\u00ednez","year":"2013","unstructured":"Rojas-Mart\u00ednez, A. et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 20, 642\u2013649 (2013).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR56","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/mt.2009.80","volume":"17","author":"P Patel","year":"2009","unstructured":"Patel, P. et al. A phase I\/II clinical trial in localized prostate cancer of an adenovirus. Mol. Ther. 17, 1292\u20131299 (2009).","journal-title":"Mol. Ther."},{"key":"1172_CR57","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/sj.cgt.7700171","volume":"7","author":"AH Djeha","year":"2000","unstructured":"Djeha, A. H. et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther. 7, 721\u2013731 (2000).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/hum.1997.8.6-709","volume":"8","author":"JA Bridgewater","year":"1997","unstructured":"Bridgewater, J. A., Knox, R. J., Pitts, J. D., Collins, M. K. & Springer, C. J. The bystander effect of the nitroreductase\/CB1954 enzyme\/prodrug system is due to a cell-permeable metabolite. Hum. Gene Ther. 8, 709\u2013717 (1997).","journal-title":"Hum. Gene Ther."},{"key":"1172_CR59","first-page":"2661","volume":"19","author":"SH Hautmann","year":"1999","unstructured":"Hautmann, S. H., Huland, E. & Huland, H. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res. 19, 2661\u20132663 (1999).","journal-title":"Anticancer Res."},{"key":"1172_CR60","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s004320050114","volume":"123","author":"S Hautmann","year":"1997","unstructured":"Hautmann, S., Huland, E. & Huland, H. Intratumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats. J. Cancer Res. Clin. Oncol. 123, 614\u2013618 (1997).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1172_CR61","first-page":"1760","volume":"54","author":"J Vieweg","year":"1994","unstructured":"Vieweg, J. et al. Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene. Cancer Res. 54, 1760\u20131765 (1994).","journal-title":"Cancer Res."},{"key":"1172_CR62","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/sj.cgt.7700626","volume":"10","author":"S Trudel","year":"2003","unstructured":"Trudel, S. et al. A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther. 10, 755\u2013763 (2003).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR63","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-11-1899","volume":"17","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde, G. et al. GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin. Cancer Res. 17, 7174\u20137182 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1172_CR64","doi-asserted-by":"publisher","first-page":"253.e21","DOI":"10.1016\/j.urolonc.2023.02.006","volume":"41","author":"M Alshalalfa","year":"2023","unstructured":"Alshalalfa, M. et al. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: a genomic analysis of primary and metastatic tumors. Urol. Oncol. 41, 253.e21\u2013253.e26 (2023).","journal-title":"Urol. Oncol."},{"key":"1172_CR65","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1128\/MCB.22.10.3345-3357.2002","volume":"22","author":"C Ren","year":"2002","unstructured":"Ren, C. et al. mRTVP-1, a novel p53 target gene with proapoptotic activities. Mol. Cell. Biol. 22, 3345\u20133357 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"1172_CR66","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.cgt.7700919","volume":"13","author":"K Naruishi","year":"2006","unstructured":"Naruishi, K. et al. Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 13, 658\u2013663 (2006).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/104303403321070793","volume":"14","author":"T Satoh","year":"2003","unstructured":"Satoh, T. et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum. Gene Ther. 14, 91\u2013101 (2003).","journal-title":"Hum. Gene Ther."},{"key":"1172_CR68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0378-1119(01)00838-1","volume":"282","author":"K Kobayashi","year":"2002","unstructured":"Kobayashi, K. et al. Reduced expression of the REIC\/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene 282, 151\u2013158 (2002).","journal-title":"Gene"},{"key":"1172_CR69","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1038\/sj.onc.1209661","volume":"25","author":"Y Kawano","year":"2006","unstructured":"Kawano, Y. et al. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 25, 6528\u20136537 (2006).","journal-title":"Oncogene"},{"key":"1172_CR70","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.1038\/sj.onc.1208138","volume":"23","author":"SY Hsieh","year":"2004","unstructured":"Hsieh, S. Y., Hsieh, P. S., Chiu, C. T. & Chen, W. Y. Dickkopf-3\/REIC functions as a suppressor gene of tumor growth. Oncogene 23, 9183\u20139189 (2004).","journal-title":"Oncogene"},{"key":"1172_CR71","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1158\/0008-5472.CAN-05-0829","volume":"65","author":"F Abarzua","year":"2005","unstructured":"Abarzua, F. et al. Adenovirus-mediated overexpression of REIC\/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase. Cancer Res. 65, 9617\u20139622 (2005).","journal-title":"Cancer Res."},{"key":"1172_CR72","doi-asserted-by":"publisher","first-page":"14236","DOI":"10.1074\/jbc.M808002200","volume":"284","author":"M Sakaguchi","year":"2009","unstructured":"Sakaguchi, M. et al. Overexpression of REIC\/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7. J. Biol. Chem. 284, 14236\u201314244 (2009).","journal-title":"J. Biol. Chem."},{"key":"1172_CR73","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/cgt.2016.53","volume":"23","author":"H Kumon","year":"2016","unstructured":"Kumon, H. et al. Adenovirus vector carrying REIC\/DKK-3 gene: neoadjuvant intraprostatic injection. Cancer Gene Ther. 23, 400\u2013409 (2016).","journal-title":"Cancer Gene Ther."},{"key":"1172_CR74","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1470-2045(26)00071-9","volume":"27","author":"TL DeWeese","year":"2026","unstructured":"DeWeese, T. L. et al. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 27, 673\u2013685 (2026).","journal-title":"Lancet Oncol."},{"key":"1172_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03541928 (2021)."},{"key":"1172_CR76","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02768363 (2021)."},{"key":"1172_CR77","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria, S., Golden, E. B. & Formenti, S. C. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 1, 1325\u20131332 (2015).","journal-title":"JAMA Oncol."},{"key":"1172_CR78","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","volume":"10","author":"SC Formenti","year":"2009","unstructured":"Formenti, S. C. & Demaria, S. Systemic effects of local radiotherapy. Lancet Oncol. 10, 718\u2013726 (2009).","journal-title":"Lancet Oncol."},{"key":"1172_CR79","first-page":"S41","volume":"123","author":"G Gejerman","year":"2025","unstructured":"Gejerman, G. et al. Phase 3, randomized, placebo controlled clinical trial of CAN-2409+prodrug in combination with standard of care external beam radiation (EBRT) for newly diagnosed localized prostate cancer. Int. J. Radiat. 123, S41 (2025).","journal-title":"Int. J. Radiat."},{"key":"1172_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cryobiol.2008.10.126","volume":"58","author":"MS Sabel","year":"2009","unstructured":"Sabel, M. S. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58, 1\u201311 (2009).","journal-title":"Cryobiology"},{"key":"1172_CR81","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2025.43.16_suppl.2504","volume":"43","author":"CJ Link","year":"2025","unstructured":"Link, C. J. et al. Clinical responses to SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 43, 2504\u20132504 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly, W. K. et al. Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study. Cancer Discov. 14, 76\u201389 (2024).","journal-title":"Cancer Discov."},{"key":"1172_CR83","doi-asserted-by":"publisher","first-page":"TPS5118","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5118","volume":"43","author":"WK Kelly","year":"2025","unstructured":"Kelly W. K. et al. Trial in progress (XALute): phase 3 study of xaluritamig vs investigator\u2019s choice of cabazitaxel or second androgen receptor directed therapy (ARDT) in post-taxane metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 43, TPS5118 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR84","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06613100 (2026)."},{"key":"1172_CR85","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO-25-00678","volume":"43","author":"MN Stein","year":"2025","unstructured":"Stein, M. N. et al. Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study. J. Clin. Oncol. 43, 2515\u20132526 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1172_CR86","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07164443 (2026)."},{"key":"1172_CR87","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT07225946 (2026)."},{"key":"1172_CR88","doi-asserted-by":"publisher","first-page":"102638","DOI":"10.1016\/j.xcrm.2026.102638","volume":"7","author":"CR Ager","year":"2026","unstructured":"Ager, C. R. et al. Neoadjuvant Fc-enhanced anti-CTLA-4 targets tregs to augment androgen deprivation in high-risk prostate cancer: a randomized phase I trial. Cell Rep. Med. 7, 102638 (2026).","journal-title":"Cell Rep. Med."},{"key":"1172_CR89","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","volume":"576","author":"CS Jansen","year":"2019","unstructured":"Jansen, C. S. et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature 576, 465\u2013470 (2019).","journal-title":"Nature"},{"key":"1172_CR90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"1172_CR91","doi-asserted-by":"publisher","first-page":"1160116","DOI":"10.3389\/fimmu.2023.1160116","volume":"14","author":"J Frankish","year":"2023","unstructured":"Frankish, J. et al. The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy. Front. Immunol. 14, 1160116 (2023).","journal-title":"Front. Immunol."},{"key":"1172_CR92","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06347705 (2026)."},{"key":"1172_CR93","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1189\/jlb.5VMR1116-491RR","volume":"102","author":"Z Lopez-Bujanda","year":"2017","unstructured":"Lopez-Bujanda, Z. & Drake, C. G. Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. J. Leukoc. Biol. 102, 393\u2013406 (2017).","journal-title":"J. Leukoc. Biol."},{"key":"1172_CR94","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1001\/jamaoncol.2024.4000","volume":"10","author":"JC Hu","year":"2024","unstructured":"Hu, J. C. et al. Transperineal vs transrectal prostate biopsy \u2014 the PREVENT randomized clinical trial. JAMA Oncol. 10, 1590\u20131593 (2024).","journal-title":"JAMA Oncol."},{"key":"1172_CR95","first-page":"173","volume":"213","author":"BV Stone","year":"2025","unstructured":"Stone, B. V. et al. Novel intraprostatic magnetic resonance-guided implantation of multidrug-eluting. J. Urol. 213, 173\u2013182 (2025).","journal-title":"J. Urol."},{"key":"1172_CR96","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","volume":"41","author":"N Pandit-Taskar","year":"2014","unstructured":"Pandit-Taskar, N. et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 41, 2093\u20132105 (2014).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01172-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:02:22Z","timestamp":1783612942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":96,"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01172-5","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"4 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}